Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of intraperitoneal ASO-4733 plus SOX for gastric cancer with peritoneal metastasis
jRCT2041250021Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASO-4733, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity, Safety and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
ASO-4733tegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2041250021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250021.